Ozempic (semaglutide) - review of pharmacological properties, mechanism of action and clinical applications
Authors:
- Anna Maria KomanAKAnna Maria Koman
- Sabina PrzygodzkaSPSabina Przygodzka
- Katarzyna GadżałaKGKatarzyna Gadżała
- Izabela JanikIJIzabela Janik
- Marzena PliszkaMPMarzena Pliszka
- Karolina Alicja PalaczKPKarolina Alicja Palacz
- Klaudia Brygida KułakKKKlaudia Brygida Kułak
- Izabela SztybórISIzabela Sztybór
- Martyna KuśmierskaMKMartyna Kuśmierska
- Katarzyna Chamera-CyrekKCKatarzyna Chamera-Cyrek
Open Access
- 10 July 2024
- journal article
- review article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 16, 52659
Abstract
Introduction: Ozempic is a new generation antihyperglycemic drug used to treat type 2 diabetes in adults whose underlying disease is not sufficiently controlled with physical activity and diet, as well as for long-term weight control in people with excess body weight and comorbidities. The aim of this study is to explore and integrate the latest literature on the analysis of the pharmacology, mechanism of action and clinical applications of Ozempic. Material and Methods of Research: A literature review focused on keywords related to the topic was performed using databases such as PubMed and Google Scholar. Results: Ozempic effectively lowers blood glucose levels and supports weight loss in patients with type 2 diabetes and obesity. Clinical trials have demonstrated its superiority over other antidiabetic medications, with significant reductions in HbA1c and body weight. Patients receiving Ozempic experienced improved glycemic control and cardiovascular outcomes, with manageable side effects. Ongoing research suggests additional benefits in cardiovascular prevention and obesity management. Conclusion: Ozempic (semaglutide) is a potent GLP-1 receptor agonist that effectively improves glycemic control and aids in weight reduction for patients with type 2 diabetes and obesity. Its practical administration, patient education, and regular monitoring are essential for optimal outcomes. Ongoing research and technological advancements, including the development of oral forms, promise to expand its applications and improve patient adherence, making Ozempic a versatile and valuable therapeutic option.Keywords
This publication has 30 references indexed in Scilit:
- Glucagon‐like peptide agonists: A prospective reviewEndocrinology, Diabetes & Metabolism, 2023
- Semaglutide for the treatment of obesityTrends in Cardiovascular Medicine, 2023
- Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetesReviews in Endocrine and Metabolic Disorders, 2022
- Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trialThe Lancet Diabetes & Endocrinology, 2019
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trialThe Lancet Diabetes & Endocrinology, 2019
- Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With SulfonylureaJAMA, 2019
- A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 DiabetesDiabetes Therapy, 2018
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 DiabetesJAMA, 2017
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trialThe Lancet Diabetes & Endocrinology, 2017
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue SemaglutideJournal of Medicinal Chemistry, 2015